DGAP-News: Apricus Biosciences Updates Presentation Time at the 2013 Stifel Nicolaus Healthcare Conference

DGAP-News: Apricus Biosciences Updates Presentation Time at the 2013 Stifel 
Nicolaus Healthcare Conference

Apricus Biosciences, Inc. 

09.09.2013 13:00

Presentation and Webcast Scheduled for September 11th at 8:00 AM ET

SAN DIEGO, 2013-09-09 13:00 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(www.apricusbio.com), today announced a change in the Company's presentation
time at the 2013 Stifel Nicolaus Healthcare Conference, being held at The Four
Seasons Hotel in Boston, MA. Richard Pascoe, Chief Executive Officer, will
present on Wednesday, September 11, 2013 at 8:00 a.m. Eastern Time. 

The presentation will be webcast and accessible to the public online at
http://www.veracast.com/webcasts/stifel/healthcare2013/23103651508.cfm or via
the Company's website at http://www.apricusbio.com. A replay will be available
for 30 days after the presentation. 

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops
innovative treatments that help large patient populations across numerous,
large-market therapeutic classes including male and female sexual health. The
Company has one approved product, Vitaros(r), for the treatment of erectile
dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus Bio's marketing partners, which include Abbott
Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG
(Sandoz), and Bracco SpA. Femprox(r), the Company's product candidate for the
treatment of female sexual interest and arousal disorder, has successfully
completed a nearly 400-subject proof-of-concept study. 

For further information on Apricus Bio, visit http://www.apricusbio.com.

         Apricus Bio Investor Relations:
         David Pitts or Lourdes Catala
         Argot Partners
News Source: NASDAQ OMX

09.09.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:     English
Company:      Apricus Biosciences, Inc.
              United States
ISIN:         US9901429525
End of Announcement                             DGAP News-Service
Press spacebar to pause and continue. Press esc to stop.